Transforming growth factor b1 is not a reliable biomarker for valvular fibrosis but could be a potential serum marker for invasiveness of prolactinomas (pilot study)

European Journal of Endocrinology

Volumn 169, Issue 3, 2013, Pages 299-306

  Elenkova, Atanaska ^a   Atanassova, Iliana ^a   Kirilov, Georgi ^a   Vasilev, Vladimir ^a   Kalinov, Krassimir ^a   Zacharieva, Sabina ^a  

^a NEW BULGARIAN UNIVERSITY   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; FETUIN A; GELATINASE A; PROLACTIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; FEMALE; FIBROTIC VALVULAR HEART DISEASE; HUMAN; INTERMETHOD COMPARISON; INVASIVENESS PROLACTINOMA; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PILOT STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN BLOOD LEVEL; RELIABILITY; SCORING SYSTEM; TUMOR VOLUME; VALVULAR HEART DISEASE;

ADULT; BIOLOGICAL MARKERS; CALCINOSIS; CASE-CONTROL STUDIES; COHORT STUDIES; DOPAMINE AGONISTS; FEMALE; FIBROSIS; HEART VALVE DISEASES; HEART VALVES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PILOT PROJECTS; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTINOMA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN; YOUNG ADULT;

EID: 84883337884     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0081     Document Type: Article

References (54)

1. Pritchett AM, Morrison JF, EdwardsWD, Schaff HV, Connolly HM & Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clinic Proceedings 2002 77 1280-1286. (doi:10.4065/77. 12.1280)
2. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C & Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003 61 859-861. (doi:10.1212/01.WNL.0000083985. 00343.F2)
3. Yamamoto M, Uesugi T & Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006 67 1225-1229. (doi:10.1212/01.wnl. 0000238508.68593.1d)
4. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 2007 356 39-46. (doi:10.1056/NEJMoa054830)
5. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ & Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000 102 2836-2841. (doi:10.1161/01.CIR.102.23.2836)
6. Kaumann AJ & Levy FO. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacology & Therapeutics 2006 111 674-706. (doi:10.1016/j.pharmthera.2005.12.004)
7. Schade R, Andersohn F, Suissa S, Haverkamp W & Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine 2007 356 29-38. (doi:10.1056/NEJMoa062222)
8. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A & Martino E. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice 2008 62 1864-1869. (doi:10.1111/j.1742-1241.2008.01779.x)
9. Herring N, Szmigielski C, Becher H, Karavitaki N & Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology 2009 70 104-108. (doi:10.1111/j.1365-2265.2008.03458.x)
10. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009 12 153-157. (doi:10.1007/s11102-008-0134-2)
11. Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clinical Endocrinology 2010 73 369-374. (doi:10.1111/j.1365-2265.2010. 03827.x)
12. Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F & Zelissen PM. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. European Journal of Endocrinology 2010 162 667-675. (doi:10.1530/EJE-09-0989)
13. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ & Pereira AM. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. Journal of Clinical Endocrinology and Metabolism 2008 93 3348-3356. (doi:10. 1210/jc.2007-2658)
14. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L & Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology 2008 159 1-5. (doi:10.1530/EJE-08-0213)
15. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A & Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology 2008 159 R11-R14. (doi:10.1530/EJE-08-0365)
16. Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, Miller KK, Utz A, Grinspoon S, Lawson EA et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clinical Endocrinology 2010 72 53-58. (doi:10.1111/j.1365-2265.2009. 03608.x)
17. Elenkova A, Shabani R, Kalinov K & Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. European Journal of Endocrinology 2012 167 17-25. (doi:10.1530/EJE-12-0121)
18. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G & Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. Journal of Clinical Endocrinology and Metabolism 2008 93 3777-3784. (doi:10.1210/jc.2007-1403)
19. Jahnichen S, Horowski R & Pertz H. Agonism at 5-HT2B receptors is not a class effect of the ergolines. European Journal of Pharmacology 2005 513 225-228. (doi:10.1016/j.ejphar.2005. 03.010)
20. Tan LC, Ng KK, Au WL, Lee RK, Chan YH & Tan NC. Bromocriptine use and the risk of valvular heart disease. Movement Disorders 2009 24 344-349. (doi:10.1002/mds.22228)
21. Boguszewski CL, Dos Santos CM, Sakamoto KS, Marini LC, de Souza AM & Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary 2011 15 44-49. (doi:10.1007/s11102-011-0339-7)
22. Shi Y & Massague J. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 2003 113 685-700. (doi:10. 1016/S0092-8674(03)00432-X)
23. Massague J. TGFb in cancer. Cell 2008 134 215-230. (doi:10. 1016/j.cell.2008.07.001)
24. Massague J. TGFb signaling in context. Nature Reviews. Molecular Cell Biology 2012 13 616-630. (doi:10.1038/nrm3434)
25. Sigel AV, Centrella M & Eghbali-Webb M. Regulation of proliferative response of cardiac fibroblasts by transforming growth factor-b1. Journal of Molecular and Cellular Cardiology 1996 28 1921-1929. (doi:10.1006/jmcc.1996. 0185)
26. Souders CA, Bowers SL & Baudino TA. Cardiac fibroblast: the renaissance cell. Circulation Research 2009 105 1164-1176. (doi:10.1161/ CIRCRESAHA.109.209809)
27. Khan R & Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-b1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006 118 10-24. (doi:10. 1111/j.1365-2567.2006.02336.x)
28. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P & Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001 104 2525-2532. (doi:10.1161/hc4601. 099489)
29. Price PA & Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of fetuin-mineral complex. Journal of Biological Chemistry 2003 278 22144-22152. (doi:10.1074/jbc.M300744200)
30. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M & Whooley MA. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007 115 2533-2539. (doi:10.1161/CIRCULATIONAHA.106.682450)
31. Cagli K, Basar N, Cagli K, Armutcu F, Aylak F, Yalcinkaya A, Erden G & Kadirogullari E. Association of serum fetuin-A with valvular calcium concentration in rheumatic mitral valve disease. Journal of Heart Valve Disease 2010 19 636-643.
32. Loh JK, Lieu AS, Su YF, Cheng CY, Tsai TH, Lin CL, Lee KS, Hwang SL, Kwan AL, Wang CJ et al. Plasma levels of transforming growth factor-b1 before and after removal of low-and high-grade astrocytomas. Cytokine 2013 61 413-418. (doi:10.1016/j.cyto. 2012.11.011)
33. Schneider T, Sailer M, Ansorge S, Firsching R & Reinhold D. Increased concentrations of transforming growth factor b1 and b2 in the plasma of patients with glioblastoma. Journal of Neuro-Oncology 2006 1 61-65. (doi:10.1007/s11060-005-9116-7)
34. Dave H, Shah M, Trivedi S & Shukla S. Prognostic utility of circulating transforming growth factor b1 in breast cancer patients. International Journal of Biological Markers 2012 27 53-59. (doi:10.5301/JBM. 2011.8736)
35. Narai S,Watanabe M, Hasegawa H, Nishibori H, Endo T, Kubota T & Kitajima M. Significance of transforming growth factor b1 as a new tumor marker for colorectal cancer. International Journal of Cancer 2002 97 508-511. (doi:10.1002/ijc.1631)
36. Lebrun JJ. Activin, TGF-b and menin in pituitary tumorigenesis. Advances in Experimental Medicine and Biology 2009 668 69-78.
37. Kaji H, Canaff L, Lebrun JJ, Goltzman D & Hendy GN. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type b signaling. PNAS 2001 98 3837-3842. (doi:10.1073/pnas.061358098)
38. Sarlis NJ, Gourgiotis L, Koch CA, Skarulis MC, Brucker-Davis F, Doppman JL, Oldfield EH & Patronas NJ. MR imaging features of thyrotropin-secreting pituitary adenomas at initial presentation. American Journal of Roentgenology 2003 181 577-582. (doi:10. 2214/ajr.181.2.1810577)
39. Roth BL. Drugs and valvular heart disease. New England Journal of Medicine 2007 356 6-9. (doi:10.1056/NEJMp068265)
40. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B & Levy RJ. Serotonin-induced up-regulation of transforming growth factorb1 via G-protein signal transduction in aortic valve interstitial cells. American Journal of Pathology 2002 161 2111-2121. (doi:10.1016/S0002-9440(10)64489-6)
41. Greene RM, Nugent P, Mukhopadhyay P, Warner DR & Pisano MM. Intracellular dynamics of Smad-mediated TGFb signaling. Journal of Cellular Physiology 2003 197 261-271. (doi:10.1002/jcp.10355)
42. Moussad EF & Brigstok DR. Connective-tissue growth factor: what's in a name? Molecular Genetics and Metabolism 2000 71 276-292. (doi:10.1006/mgme. 2000.3059)
43. Stawowy P, Margeta C, Kallish H, Seidah NG, Chretien M, Fleck E & Graf K. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-b1 involves furin-convertase. Cardiovascular Research 2004 63 87-97. (doi:10.1016/j.cardiores. 2004.03.010)
44. Attaran S, Sherwood R, Dastidar MG & El-Gamel A. Identification of low circulatory transforming growth factor b1 in patients with degenerative heart valve disease. Interactive Cardiovascular and Thoracic Surgery 2010 11 791-793. (doi:10.1510/icvts.2010. 244384)
45. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM & Chauhan A. The serum concentration of active TGF-b1 is severely depressed in advanced atherosclerosis. Nature Medicine 1995 1 74-79. (doi:10.1038/nm0195-74)
46. Tashiro H, Shimokawa H, Yamamoto K, Momohara M, Tada H & Takeshita A. Altered plasma levels of cytokines in patients with ischemic heart disease. Coronary Artery Disease 1997 8 143-147. (doi:10.1097/00019501-199703000-00004)
47. Stoll P, Wuertemberger U, Bratke K, Zingler C, Virchow CJ & Lommatzsch M. Stage-dependent association of BDNF and TGF-b1 with lung function in stable COPD. Respiratory Research 2012 13 116. (doi:10.1186/1465-9921-13-116)
48. Jakus? V, Sapak M & Kostolanska J. Circulating TGF-b1, glycation, and oxidation in children with diabetes mellitus type 1. Experimental Diabetes Research 2012 2012. Article ID 510902. (doi:10.1155/2012/510902)
49. Joseph J, Benedict S, Badrinath P, Wassef S, Joseph M, Abdulkhalik S & Nicholls MG. Elevation of plasma transforming growth factor b1 levels in stable nonatopic asthma. Annals of Allergy, Asthma & Immunology 2003 91 472-476. (doi:10.1016/S1081-1206(10)61516-5)
50. Shi M, Yu B, Gao H, Mu J & Ji C. Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a metaanalysis. Molecular Biology Reports 2013 40 617-623. (doi:10. 1007/s11033-012-2100-3)
51. Sarkar DK, Chaturvedi K, Oomizu S, Boyadjieva NI & Chen CP. Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-b1, and TGF-b type II receptor interact to inhibit the growth of pituitary lactotropes. Endocrinology 2005 146 4179-4188. (doi:10.1210/en.2005-0430)
52. Coya R, Alvarez CV, Perez F, Gianzo C & Dieguez C. Effects of TGFb1 on prolactin synthesis and secretion: an in-vitro study. Journal of Neuroendocrinology 1999 11 351-360. (doi:10.1046/j.1365-2826.1999.00336.x)
53. Jiang M, Mou CZ, Han T, Wang M & Yang W. Thrombospondin-1 and transforming growth factor-b1 levels in prolactinoma and their clinical significance. Journal of International Medical Research 2012 40 1284-1294. (doi:10.1177/147323001204000407)
54. Mete O, Ezzat S & Asa SL. Biomarkers of aggressive pituitary adenomas. Journal of Molecular Endocrinology 2012 49 R69-R78. (doi:10.1530/JME-12-0113)